Clinical Trials
Head-to-head trial data in rheumatoid arthritis scant, offer ‘shaky evidence’
SAN DIEGO — Rheumatology research still offers too few head-to-head clinical trials of biologic medications to help clinicians manage rheumatoid arthritis, according to data presented at the 2023 Congress of Clinical Rheumatology West.
Positive topline results reported in clinical trial of novel myotonic dystrophy drug
A global clinical-stage specialty biopharmaceutical company has announced positive topline results from its study of its investigational therapeutic AM0-02 to treat children and adolescents with congenital myotonic dystrophy.
Positive data reported from clinical trials of novel therapeutic for Dravet syndrome
Stoke Therapeutics Inc. has announced new positive data regarding its proprietary antisense oligonucleotide therapeutic to treat Dravet syndrome.
Positive results announced from phase 1 trial of novel IV therapeutic for acute TBI
A Philadelphia-area contract research organization has announced completion of a phase 1 clinical trial of CMX-2043, Ischemix Inc.’s novel, proprietary cytoprotective drug candidate to treat acute traumatic brain injury.
The Science of Clinical Trials with Cardinal Health
In this episode, host Shikha Jain, MD, speaks with Cardinal Health’s Parisa Asgarisabet, PhD and Scott Swain, PhD, MPH about benefits and uses of real-world evidence, the issue of diversity in clinical trials and more.
Study of stem cell-derived Parkinson’s therapy yields positive results after 1 year
Positive data from a phase 1 clinical trial for bemdaneprocel, a stem cell-derived investigational therapeutic for treating Parkinson’s disease, have been announced by its manufacturer.
Industry-funded meta-analyses more likely to have favorable conclusions
Industry-funded meta-analyses published in oncology journals reported favorable conclusions more frequently than those with no industry funding, according to findings published in JAMA Network Open.
Venglustat nonsuperior to placebo after 1 year for GBA1-associated Parkinson’s disease
Although generally safe and well-tolerated, venglustat treatment for adults with GBA-1 associated Parkinson’s disease was not superior to placebo after 1 year, per data from the Lancet Neurology.
Partnership announces addition of novel cancer-killing biologic to glioblastoma trial
A California-based nonprofit and a biotechnology firm announced the activation of novel biologic ADI-PEG 20 in the GBM AGILE platform trial, a study that evaluates therapies for individuals with newly diagnosed or recurring glioblastoma.
FDA approves Ingrezza for chorea associated with Huntington’s disease
The FDA has approved once-daily Ingrezza capsules for adults with chorea associated with Huntington’s disease.